Accelerometer-Based Sedentary Time, Physical Activity, and Serum Metabolome in Young Men
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Participants
4.2. Objectively Measured Physical Activity and Sedentary Time
4.3. Serum Metabolome
4.4. Demographic and Confounding Variables
4.5. Statistics
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Booth, F.W.; Roberts, C.K.; Laye, M.J. Lack of exercise is a major cause of chronic diseases. Compr. Physiol. 2012, 2, 1143–1211. [Google Scholar] [PubMed] [Green Version]
- Whooten, R.; Kerem, L.; Stanley, T. Physical activity in adolescents and children and relationship to metabolic health. Curr. Opin. Endocrinol. Diabetes Obes. 2019, 1, 25–31. [Google Scholar] [CrossRef] [PubMed]
- Kelly, R.S.; Kelly, M.P.; Kelly, P. Metabolomics, physical activity, exercise and health: A review of the current evidence. Biochim. Biophys. Acta Mol. Basis Dis. 2020, 12, 165936. [Google Scholar] [CrossRef] [PubMed]
- Contrepois, K.; Wu, S.; Moneghetti, K.J.; Hornburg, D.; Ahadi, S.; Tsai, M.S.; Metwally, A.A.; Wei, E.; Lee-McMullen, B.; Quijada, J.V.; et al. Molecular Choreography of Acute Exercise. Cell 2020, 5, 1112–1130. [Google Scholar] [CrossRef]
- Lee, I.M.; Shiroma, E.J.; Lobelo, F.; Puska, P.; Blair, S.N.; Katzmarzyk, P.T.; Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of disease and life expectancy. Lancet 2012, 9838, 219–229. [Google Scholar] [CrossRef] [Green Version]
- Kujala, U.M.; Mäkinen, V.-P.; Heinonen, I.; Soininen, P.; Kangas, A.J.; Leskinen, T.H.; Rahkila, P.; Würtz, P.; Kovanen, V.; Cheng, S.; et al. Long-term Leisure-time Physical Activity and Serum Metabolome. Circulation 2013, 127, 340–348. [Google Scholar] [CrossRef] [Green Version]
- Xiao, Q.; Moore, S.C.; Keadle, S.K.; Xiang, Y.B.; Zheng, W.; Peters, T.M.; Leitzmann, M.F.; Ji, B.T.; Sampson, J.N.; Shu, X.O.; et al. Objectively measured physical activity and plasma metabolomics in the Shanghai Physical Activity Study. Int. J. Epidemiol. 2016, 5, 1433–1444. [Google Scholar] [CrossRef]
- Fukai, K.; Harada, S.; Iida, M.; Kurihara, A.; Takeuchi, A.; Kuwabara, K.; Sugiyama, D.; Okamura, T.; Akiyama, M.; Nishiwaki, Y.; et al. Metabolic Profiling of Total Physical Activity and Sedentary Behavior in Community-Dwelling Men. PLoS ONE 2016, 10, e0164877. [Google Scholar] [CrossRef] [Green Version]
- Ding, M.; Zeleznik, O.A.; Guasch-Ferre, M.; Hu, J.; Lasky-Su, J.; Lee, I.M.; Jackson, R.D.; Shadyab, A.H.; LaMonte, M.J.; Clish, C.; et al. Metabolome-Wide Association Study of the Relationship Between Habitual Physical Activity and Plasma Metabolite Levels. Am. J. Epidemiol. 2019, 11, 1932–1943. [Google Scholar] [CrossRef]
- Bell, J.A.; Hamer, M.; Richmond, R.C.; Timpson, N.J.; Carslake, D.; Davey Smith, G. Associations of device-measured physical activity across adolescence with metabolic traits: Prospective cohort study. PLoS Med. 2018, 9, e1002649. [Google Scholar] [CrossRef] [Green Version]
- Pang, Y.; Kartsonaki, C.; Du, H.; Millwood, I.Y.; Guo, Y.; Chen, Y.; Bian, Z.; Yang, L.; Walters, R.; Bragg, F.; et al. Physical Activity, Sedentary Leisure Time, Circulating Metabolic Markers, and Risk of Major Vascular Diseases. Circ. Genom. Precis. Med. 2019, 9, 386–396. [Google Scholar] [CrossRef] [Green Version]
- Zheng, H.; Yde, C.C.; Arnberg, K.; Mølgaard, C.; Michaelsen, K.F.; Larnkjær, A.; Bertram, H.C. NMR-based metabolomic profiling of overweight adolescents: An elucidation of the effects of inter-/intraindividual differences, gender, and pubertal development. BioMed Res. Int. 2014, 2014, 537157. [Google Scholar] [CrossRef]
- Jones, P.R.; Rajalahti, T.; Resaland, G.K.; Aadland, E.; Steene-Johannessen, J.; Anderssen, S.A.; Bathen, T.F.; Andreassen, T.; Kvalheim, O.M.; Ekelund, U. Associations of lipoprotein particle profile and objectively measured physical activity and sedentary time in schoolchildren: A prospective cohort study. Int. J. Behav. Nutr. Phys. Act. 2022, 1, 5. [Google Scholar] [CrossRef]
- Kujala, U.M.; Vaara, J.P.; Kainulainen, H.; Vasankari, T.; Vaara, E.; Kyröläinen, H. Associations of aerobic fitness and maximal muscular strength with metabolites in young men. JAMA Netw. Open 2019, 8, e198265. [Google Scholar] [CrossRef]
- Kainulainen, H.; Hulmi, J.J.; Kujala, U.M. Potential role of branched-chain amino acid catabolism in regulating fat oxidation. Exerc. Sport Sci. Rev. 2013, 41, 194–200. [Google Scholar] [CrossRef]
- Harris, R.A.; Joshi, M.; Jeoung, N.H.; Obayashi, M. Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. J. Nutr. 2005, 135, 1527–1530S. [Google Scholar] [CrossRef] [Green Version]
- Chastin, S.F.M.; De Craemer, M.; De Cocker, K.; Powell, L.; Van Cauwenberg, J.; Dall, P.; Hamer, M.; Stamatakis, E. How does light-intensity physical activity associate with adult cardiometabolic health and mortality? Systematic review with meta-analysis of experimental and observational studies. Br. J. Sports Med. 2019, 6, 370–376. [Google Scholar] [CrossRef] [Green Version]
- Kodama, S.; Tanaka, S.; Saito, K.; Shu, M.; Sone, Y.; Onitake, F.; Suzuki, E.; Shimano, H.; Yamamoto, S.; Kondo, K.; et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: Ameta-analysis. Arch. Intern. Med. 2007, 10, 999–1008. [Google Scholar] [CrossRef] [Green Version]
- Huttunen, J.K.; Länsimies, E.; Voutilainen, E.; Ehnholm, C.; Hietanen, E.; Penttilä, I.; Siitonen, O.; Rauramaa, R. Effect of moderate physical exercise on serum lipoproteins. A controlled clinical trial with special reference to serum high-density lipoproteins. Circulation 1979, 6, 1220–1229. [Google Scholar] [CrossRef] [Green Version]
- Lehti, M.; Donelan, E.; Abplanalp, W.; Al-Massadi, O.; Habegger, H.M.; Weber, J.; Ress, C.; Mansfeld, J.; Somvanshi, S.; Trivedi, C.; et al. High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation 2013, 22, 2364–2371. [Google Scholar] [CrossRef] [Green Version]
- Brocklebank, L.A.; Falconer, C.L.; Page, A.S.; Perry, R.; Cooper, A.R. Accelerometer-measured sedentary time and cardiometabolic biomarkers: A systematic review. Prev. Med. 2015, 76, 92–102. [Google Scholar] [CrossRef] [Green Version]
- Healy, G.N.; Matthews, C.E.; Dunstan, D.W.; Winkler, E.A.; Owen, N. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06. Eur. Heart J. 2011, 5, 590–597. [Google Scholar] [CrossRef]
- Ross, R.; Blair, S.N.; Arena, R.; Church, T.S.; Després, J.P.; Franklin, B.A.; Haskell, W.L.; Kaminsky, L.A.; Levine, B.D.; Lavie, C.J.; et al. Importance of assessing cardiorespiratory fitness in clinical practice: A case for fitness as a clinical vital sign: A scientific statement from the American Heart Association. Circulation 2016, 24, e653–e699. [Google Scholar] [CrossRef]
- De Lannoy, L.; Sui, X.; Blair, S.N.; Ross, R. All-cause mortality risk among active and inactive adults matched for cardiorespiratory fitness. Eur. J. Prev. Cardiol. 2019, 5, 554–556. [Google Scholar] [CrossRef]
- Blair, S.N.; Cheng, Y.; Holder, J.S. Is physical activity or physical fitness more important in defining health benefits? Med. Sci. Sports Exerc. 2001, 33, S379–S399. [Google Scholar] [CrossRef]
- Sassen, B.; Cornelissen, V.A.; Kiers, H.; Wittink, H.; Kok, G.; Vanhees, L. Physical fitness matters more than physical activity in controlling cardiovascular disease risk factors. Eur. J. Cardiovasc. Prev. Rehabil. 2009, 6, 677–683. [Google Scholar] [CrossRef]
- Brennan, A.M.; Benson, M.; Morningstar, J.; Herzig, M.; Robbins, J.; Gerszten, R.E.; Ross, R. Plasma Metabolite Profiles in Response to Chronic Exercise. Med. Sci. Sports Exerc. 2018, 7, 1480–1486. [Google Scholar] [CrossRef]
- Vähä-Ypyä, H.; Vasankari, T.; Husu, P.; Suni, J.; Sievänen, H. A universal, accurate intensity-based classification of different physical activities using raw data of accelerometer. Clin. Physiol. Funct. Imaging 2015, 35, 64–70. [Google Scholar] [CrossRef]
- Vähä-Ypyä, H.; Vasankari, T.; Husu, P.; Mänttäri, A.; Vuorimaa, T.; Suni, J.; Sievänen, H. Validation of cut-points for evaluating the intensity of physical activity with accelerometry-based Mean Amplitude Deviation (MAD). PLoS ONE 2015, 10, e0134813. [Google Scholar] [CrossRef] [Green Version]
- Husu, P.; Tokola, K.; Vähä-Ypyä, H.; Sievänen, H.; Suni, J.; Heinonen, O.; Heiskanen, J.; Kaikkonen, P.; Savonen, K.; Kokko, S.; et al. Physical activity, sedentary behavior and bedtime among Finnish adults measured 24/7 by tri-axial accelerometry. J. Meas. Phys. Behav. 2021, 4, 163–173. [Google Scholar] [CrossRef]
- Vähä-Ypyä, H.; Husu, P.; Suni, J.; Vasankari, T.; Sievänen, H. Reliable recognition of lying, sitting, and standing with a hip-worn accelerometer. Scand. J. Med. Sci. Sports 2018, 28, 1092–1102. [Google Scholar] [CrossRef] [Green Version]
- Soininen, P.; Kangas, A.J.; Wurtz, P.; Tukiainen, T.; Tynkkynen, T.; Laatikainen, R.; Järvelin, M.R.; Kähönen, M.; Lehtimäki, T.; Viikari, J.; et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009, 9, 1781–1785. [Google Scholar] [CrossRef] [PubMed]
- Soininen, P.; Kangas, A.J.; Wurtz, P.; Suna., T.; Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ. Cardiovasc. Genet. 2015, 1, 192–206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chastin, S.F.M.; Palarea-Albaladejo, J.; Dontje, M.L.; Skelton, D.A. Combined effects of time spent in physical activity, sedentary behaviors and sleep on obesity and cardio-metabolic health markers: A novel compositional data analysis approach. PLoS ONE 2015, 10, e0139984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Characteristics | Mean (Standard Deviation) | 95% Confidence Interval |
---|---|---|
Age in years | 28.2 (7.3) | 27.4–29.0 |
Smokers, n (%) | 75 (24.0) | 19.6–29.0 * |
Sedentary time | ||
Total sedentary time (min) | 707.6 (127.3) | 693.5–721.8 |
Total sedentary time (relative to accelerometer wear time, %) | 77.6 (8.0) | 76.8–78.5 |
Physical activity (min) | ||
Light Activity (1.5–3 MET) (min) | 119.8 (47.1) | 114.6–125.1 |
Moderate Activity (3–6 MET) (min) | 77.8 (32.4) | 74.2–81.4 |
Vigorous Activity (>6 MET) (min) | 4.4 (6.3) | 3.7–5.1 |
Moderate-to-Vigorous Activity (≥3 MET) (min) | 82.1 (34.0) | 78.4–85.9 |
Physical activity relative to accelerometer wear time (%) | ||
Light Activity (1.5–3 MET) (%) | 13.2 (5.1) | 12.7–13.8 |
Moderate Activity (3–6 MET) (%) | 8.6 (3.6) | 8.2–9.0 |
Vigorous Activity (>6 MET) (%) | 0.48 (0.67) | 0.41–0.56 |
Moderate-to-Vigorous Activity (≥3 MET) (%) | 9.1 (3.8) | 8.7–9.5 |
Sedentary Time | Light Intensity Physical Activity | Moderate-to-Vigorous Physical Activity | ||||
---|---|---|---|---|---|---|
Metabolome Measure | β (95% CI) | p-Value | β (95% CI) | p-Value | β (95% CI) | p-Value |
Lipoprotein particle concentration | ||||||
ǂ Extremely large VLDL | 0.07 (−0.03; 0.16) | 0.191 | −0.07 (−0.16; 0.03) | 0.150 | −0.05 (−0.16; 0.06) | 0.345 |
ǂ Very large VLDL | 0.09 (−0.02; 0.20) | 0.111 | −0.10 (−0.21; 0.02) | 0.089 | −0.06 (−0.16; 0.05) | 0.285 |
* Large VLDL | 0.06 (−0.06; 0.17) | 0.342 | −0.06 (−0.19; 0.06) | 0.314 | −0.06 (−0.17; 0.05) | 0.296 |
ǂ Medium VLDL | 0.08 (−0.04; 0.21) | 0.196 | −0.09 (−0.21; 0.04) | 0.188 | −0.08 (−0.21; 0.04) | 0.196 |
Small VLDL | 0.08 (−0.02; 0.18) | 0.099 | −0.09 (−0.19; 0.01) | 0.085 | −0.06 (−0.16; 0.04) | 0.225 |
Very small VLDL | 0.12 (0.02; 0.22) | 0.021 | −0.11 (−0.21; 0.00) | 0.043 | −0.11 (−0.21; −0.01) | 0.028 |
IDL | 0.11 (0.01; 0.21) | 0.040 | −0.09 (−0.19; 0.02) | 0.108 | −0.11 (−0.22; −0.01) | 0.027 |
Large LDL | 0.10 (−0.00; 0.21) | 0.055 | −0.08 (−0.19; 0.03) | 0.140 | −0.11 (−0.21; −0.01) | 0.037 |
Medium LDL | 0.10 (−0.00; 0.20) | 0.059 | −0.08 (−0.19; 0.03) | 0.142 | −0.11 (−0.21; −0.00) | 0.042 |
Small LDL | 0.10 (−0.01; 0.20) | 0.072 | −0.08 (−0.19; 0.03) | 0.144 | −0.10 (−0.20; 0.005) | 0.062 |
Very large HDL | −0.09 (−0.20; 0.02) | 0.128 | 0.06 (−0.06; 0.17) | 0.333 | 0.11 (−0.00; 0.21) | 0.055 |
Large HDL | −0.13 (−0.24; −0.02) | 0.022 | 0.09 (−0.02; 0.21) | 0.112 | 0.15 (0.04; 0.26) | 0.006 |
Medium HDL | −0.08 (−0.19; 0.03) | 0.147 | 0.06 (−0.05; 0.18) | 0.298 | 0.09 (−0.02; 0.20) | 0.094 |
Small HDL | 0.04 (−0.07; 0.15) | 0.487 | −0.03 (−0.15; 0.08) | 0.582 | −0.04 (−0.15; 0.07) | 0.462 |
Lipoprotein particle size | ||||||
VLDL diameter | 0.05 (−0.06; 0.16) | 0.401 | −0.06 (−0.18; 0.06) | 0.305 | −0.02 (−0.14; 0.09) | 0.669 |
LDL diameter | −0.02 (−0.13; 0.09) | 0.759 | 0.04 (−0.07; 0.16) | 0.443 | −0.02 (−0.13; 0.09) | 0.728 |
HDL diameter | −0.11 (−0.22; −0.01) | 0.040 | 0.08 (−0.03; 0.20) | 0.148 | 0.13 (0.02; 0.24) | 0.016 |
Apolipoproteins | ||||||
ApoA1 | −0.09 (−0.20; 0.02) | 0.120 | 0.05 (−0.06; 0.17) | 0.372 | 0.12 (0.01; 0.23) | 0.037 |
ApoB | 0.10 (−0.00; 0.21) | 0.056 | −0.10 (−0.20; 0.01) | 0.081 | −0.09 (−0.19; 0.01) | 0.085 |
ApoB ApoA1 ratio | 0.14 (0.03; 0.24) | 0.012 | −0.12 (−0.23; −0.01) | 0.034 | −0.13 (−0.24; −0.03) | 0.012 |
Triglycerides | ||||||
ǂ Total triglycerides | 0.12 (−0.00; 0.24) | 0.055 | −0.10 (−0.22; 0.02) | 0.090 | −0.05 (−0.17; 0.07) | 0.446 |
ǂ VLDL TG | 0.07 (−0.06; 0.19) | 0.300 | −0.07 (−0.19; 0.06) | 0.308 | −0.06 (−0.18; 0.07) | 0.390 |
IDL TG | 0.18 (0.08; 0.27) | <0.001 * | −0.16 (−0.25; −0.06) | 0.001 * | −0.16 (−0.26; −0.07) | <0.001 * |
LDL TG | 0.15 (0.06; 0.25) | 0.001 * | −0.14 (−0.23; −0.04) | 0.005 | −0.15 (−0.24; −0.05) | 0.002 * |
HDL TG | 0.03 (−0.07; 0.12) | 0.573 | −0.05 (−0.15; 0.05) | 0.339 | 0.00 (−0.09; 0.10) | 0.953 |
Cholesterol | ||||||
Total cholesterol | 0.07 (−0.04; 0.17) | 0.207 | −0.06 (−0.17; 0.05) | 0.269 | −0.06 (−0.17; 0.04) | 0.230 |
VLDL-C | 0.08 (−0.03; 0.19) | 0.137 | −0.09 (−0.19; 0.02) | 0.120 | −0.06 (−0.16; 0.05) | 0.275 |
IDL-C | 0.10 (−0.01; 0.20) | 0.064 | −0.08 (−0.19; 0.03) | 0.160 | −0.11 (−0.21; −0.00) | 0.041 |
LDL-C | 0.10 (−0.01; 0.20) | 0.074 | −0.07 (−0.18; 0.03) | 0.179 | −0.10 (−0.21; −0.00) | 0.047 |
HDL-C | −0.11 (−0.22; 0.01) | 0.064 | 0.08 (−0.04; 0.19) | 0.194 | 0.12 (0.01; 0.23) | 0.029 |
HDL2-C | −0.11 (−0.22; −0.00) | 0.046 | 0.08 (−0.03; 0.20) | 0.149 | 0.13 (0.02; 0.24) | 0.022 |
HDL3-C | 0.02 (−0.09; 0.13) | 0.731 | −0.04 (−0.15; 0.07) | 0.517 | 0.01 (−0.10; 0.11) | 0.905 |
Esterified cholesterol | 0.07 (−0.04; 0.17) | 0.217 | −0.06 (−0.17; 0.05) | 0.283 | −0.06 (−0.17; 0.04) | 0.237 |
Free cholesterol | 0.07 (−0.03; 0.17) | 0.187 | −0.06 (−0.17; 0.04) | 0.239 | −0.06 (−0.17; 0.04) | 0.219 |
Fatty acids | ||||||
Total fatty acids | 0.07 (−0.04; 0.17) | 0.207 | −0.08 (−0.19; 0.03) | 0.142 | −0.04 (−0.14; 0.06) | 0.462 |
Unsaturation degree | −0.12 (−0.23; −0.01) | 0.028 | 0.12 (0.01; 0.23) | 0.031 | 0.10 (−0.01; 0.20) | 0.074 |
Omega-3 FA | 0.01 (−0.09; 0.12) | 0.831 | −0.02 (−0.13; 0.09) | 0.732 | 0.00 (−0.10; 0.10) | 0.999 |
Omega-3 FA ratio | −0.08 (−0.18; 0.03) | 0.168 | 0.07 (−0.04; 0.19) | 0.193 | 0.06 (−0.04; 0.17) | 0.233 |
Docosahexaenoic acid | 0.04 (−0.07; 0.14) | 0.466 | −0.05 (−0.15; 0.06) | 0.379 | −0.02 (−0.12; 0.08) | 0.700 |
Polyunsaturated FA | 0.05 (−0.06; 0.15) | 0.372 | −0.06 (−0.16; 0.05) | 0.311 | −0.03 (−0.13; 0.07) | 0.580 |
Omega-6 FA | 0.05 (−0.05; 0.16) | 0.320 | −0.06 (−0.17; 0.05) | 0.267 | −0.03 (−0.14; 0.07) | 0.522 |
Omega-6 FA ratio | −0.09 (−0.20; 0.02) | 0.126 | 0.10 (−0.02; 0.21) | 0.093 | 0.06 (−0.05; 0.16) | 0.307 |
Linoleic acid | 0.05 (−0.06; 0.15) | 0.372 | −0.06 (−0.17; 0.05) | 0.290 | −0.03 (−0.13; 0.08) | 0.620 |
Saturated FA | 0.08 (−0.02; 0.19) | 0.124 | −0.09 (−0.20; 0.01) | 0.088 | −0.05 (−0.16; 0.05) | 0.315 |
Saturated FA ratio | 0.13 (0.02; 0.25) | 0.025 | −0.12 (−0.24; 0.00) | 0.051 | −0.12 (−0.24; −0.01) | 0.032 |
Monounsaturated FA | 0.06 (−0.04; 0.17) | 0.235 | −0.08 (−0.19; 0.03) | 0.136 | −0.03 (−0.13; 0.08) | 0.577 |
Metabolic substrates | ||||||
Glucose | −0.09 (−0.19; 0.01) | 0.086 | 0.11 (0.01; 0.21) | 0.035 | 0.04 (−0.06; 0.14) | 0.390 |
Glycerol | 0.11 (0.00; 0.22) | 0.041 | −0.08 (−0.19; 0.03) | 0.175 | −0.13 (−0.24; −0.03) | 0.012 |
Acetoacetate | −0.02 (−0.13; 0.09) | 0.724 | 0.02 (−0.09; 0.14) | 0.674 | 0.01 (−0.10; 0.12) | 0.847 |
ǂ 3-hydroxybuturate | 0.13 (0.05; 0.21) | 0.002 * | −0.11 (−0.20; −0.03) | 0.011 | −0.13 (−0.21; −0.05) | 0.001 * |
ǂ Acetate | 0.16 (0.05; 0.26) | 0.003 | −0.16 (−0.27; −0.05) | 0.003 | −0.15 (−0.25; −0.05) | 0.003 |
Citrate | 0.00 (−0.11; 0.11) | 0.996 | −0.02 (−0.14; 0.10) | 0.725 | 0.03 (−0.09; 0.14) | 0.658 |
Lactate | 0.08 (−0.03; 0.18) | 0.148 | −0.10 (−0.20; 0.01) | 0.067 | −0.03 (−0.13; 0.07) | 0.514 |
Pyruvate | 0.04 (−0.06; 0.14) | 0.403 | 0.00 (−0.10; 0.11) | 0.957 | −0.09 (−0.19; 0.01) | 0.070 |
Amino acids | ||||||
Isoleucine (BCAA) | 0.10 (−0.01; 0.22) | 0.081 | −0.11 (−0.23; 0.01) | 0.062 | −0.07 (−0.18; 0.04) | 0.217 |
Leucine (BCAA) | 0.13 (0.02; 0.24) | 0.024 | −0.14 (−0.26; −0.02) | 0.019 | −0.10 (−0.21; 0.02) | 0.092 |
Valine | 0.16 (0.05; 0.27) | 0.004 | −0.16 (−0.27; −0.05) | 0.006 | −0.13 (−0.24; −0.02) | 0.018 |
Alanine | 0.02 (−0.09; 0.14) | 0.674 | −0.05 (−0.17; 0.06) | 0.379 | 0.01 (−0.10; 0.12) | 0.798 |
Glutamine | −0.19 (−0.29; −0.09) | <0.001 | 0.20 (0.10; 0.30) | <0.001 * | 0.13 (0.04; 0.23) | 0.008 |
Glycine | −0.07 (−0.18; 0.04) | 0.185 | 0.08 (−0.03; 0.19) | 0.167 | 0.05 (−0.05; 0.16) | 0.330 |
Histidine | 0.03 (−0.09; 0.14) | 0.664 | −0.06 (−0.17; 0.06) | 0.351 | 0.02 (−0.09; 0.13) | 0.767 |
Phenylalanine | 0.04 (−0.07; 0.16) | 0.444 | −0.05 (−0.17; 0.06) | 0.378 | −0.03 (−0.14; 0.08) | 0.647 |
Tyrosine | −0.06 (−0.17; 0.06) | 0.317 | 0.06 (−0.06; 0.17) | 0.357 | 0.05 (−0.06; 0.16) | 0.372 |
Miscellaneous | ||||||
Glycoproteins | 0.07 (−0.04; 0.18) | 0.193 | −0.05 (−0.16; 0.06) | 0.342 | −0.08 (−0.19; 0.03) | 0.137 |
Creatinine | 0.06 (−0.05; 0.17) | 0.290 | −0.08 (−0.20; 0.03) | 0.165 | −0.02 (−0.13; 0.09) | 0.681 |
Albumin | 0.02 (−0.08; 0.11) | 0.762 | −0.05 (−0.15; 0.05) | 0.345 | 0.03 (−0.07; 0.13) | 0.560 |
Sedentary Time | Light Intensity Physical Activity | Moderate-to-Vigorous Physical Activity | ||||
---|---|---|---|---|---|---|
Metabolome Measure | γ | p-Value | γ | p-Value | γ | p-Value |
Lipoprotein particle concentration | ||||||
ǂ Extremely large VLDL | 0.091 | 0.458 | −0.284 | 0.157 | 0.194 | 0.289 |
ǂ Very large VLDL | 0.130 | 0.354 | −0.351 | 0.127 | 0.221 | 0.290 |
ǂ Large VLDL | 0.111 | 0.440 | −0.235 | 0.316 | 0.124 | 0.559 |
ǂ Medium VLDL | 0.177 | 0.251 | −0.141 | 0.576 | −0.036 | 0.875 |
Small VLDL | 0.221 | 0.082 | −0.265 | 0.201 | 0.044 | 0.817 |
Very small VLDL | 0.305 | 0.018 | −0.142 | 0.499 | −0.163 | 0.395 |
IDL | 0.270 | 0.041 | −0.010 | 0.961 | −0.259 | 0.186 |
Large LDL | 0.252 | 0.059 | 0.002 | 0.994 | −0.253 | 0.200 |
Medium LDL | 0.248 | 0.063 | −0.010 | 0.965 | −0.238 | 0.229 |
Small LDL | 0.237 | 0.076 | −0.049 | 0.823 | −0.188 | 0.342 |
Very large HDL | −0.164 | 0.228 | −0.135 | 0.541 | 0.299 | 0.138 |
Large HDL | −0.332 | 0.018 | −0.116 | 0.610 | 0.448 | 0.031 |
Medium HDL | −0.249 | 0.079 | −0.187 | 0.419 | 0.436 | 0.039 |
Small HDL | 0.076 | 0.594 | −0.174 | 0.456 | 0.098 | 0.643 |
Lipoprotein particle size | ||||||
VLDL diameter | 0.114 | 0.431 | −0.238 | 0.314 | 0.124 | 0.563 |
LDL diameter | −0.037 | 0.794 | 0.344 | 0.136 | −0.307 | 0.143 |
HDL diameter | −0.300 | 0.031 | −0.075 | 0.743 | 0.374 | 0.071 |
Apolipoproteins | ||||||
ApoA1 | −0.243 | 0.088 | −0.237 | 0.310 | 0.480 | 0.024 |
ApoB | 0.265 | 0.048 | −0.141 | 0.519 | −0.124 | 0.533 |
ApoB ApoA1 ratio | 0.358 | 0.008 | −0.059 | 0.787 | −0.299 | 0.134 |
Triglycerides | ||||||
ǂ Total triglycerides | 0.245 | 0.105 | −0.430 | 0.083 | 0.185 | 0.411 |
ǂ VLDL TG | 0.133 | 0.383 | −0.248 | 0.320 | 0.115 | 0.612 |
IDL TG | 0.444 | <0.001 * | −0.203 | 0.293 | −0.240 | 0.173 |
LDL TG | 0.386 | 0.001 * | −0.166 | 0.391 | −0.219 | 0.215 |
HDL TG | 0.088 | 0.474 | −0.284 | 0.156 | 0.196 | 0.283 |
Cholesterol | ||||||
Total cholesterol | 0.164 | 0.222 | −0.086 | 0.695 | −0.078 | 0.697 |
VLDL-C | 0.219 | 0.104 | −0.218 | 0.323 | −0.001 | 0.997 |
IDL-C | 0.244 | 0.068 | 0.018 | 0.933 | −0.262 | 0.187 |
LDL-C | 0.235 | 0.080 | 0.020 | 0.927 | −0.255 | 0.202 |
HDL-C | −0.289 | 0.042 | −0.134 | 0.564 | 0.424 | 0.046 |
HDL2-C | −0.309 | 0.029 | −0.111 | 0.630 | 0.420 | 0.046 |
HDL3-C | 0.045 | 0.746 | −0.284 | 0.211 | 0.239 | 0.246 |
Esterified cholesterol | 0.160 | 0.235 | −0.085 | 0.221 | −0.075 | 0.201 |
Free cholesterol | 0.172 | 0.196 | −0.088 | 0.688 | −0.084 | 0.670 |
Fatty acids | ||||||
Total fatty acids | 0.179 | 0.183 | −0.282 | 0.200 | 0.103 | 0.606 |
Unsaturation degree | −0.295 | 0.033 | 0.269 | 0.235 | 0.026 | 0.898 |
Omega-3 FA | 0.040 | 0.764 | −0.114 | 0.602 | 0.074 | 0.710 |
Omega-3 FA ratio | −0.178 | 0.198 | 0.119 | 0.598 | 0.059 | 0.776 |
Docosahexaenoic acid | 0.106 | 0.423 | −0.199 | 0.359 | 0.093 | 0.638 |
Polyunsaturated FA | 0.124 | 0.354 | −0.201 | 0.358 | 0.077 | 0.697 |
Omega-6 FA | 0.137 | 0.308 | −0.213 | 0.332 | 0.076 | 0.702 |
Omega-6 FA ratio | −0.212 | 0.131 | 0.286 | 0.214 | −0.074 | 0.725 |
Linoleic acid | 0.125 | 0.355 | −0.236 | 0.287 | 0.111 | 0.581 |
Saturated FA | 0.221 | 0.101 | −0.292 | 0.187 | 0.070 | 0.725 |
Saturated FA ratio | 0.352 | 0.016 | −0.092 | 0.702 | −0.261 | 0.231 |
Monounsaturated FA | 0.170 | 0.210 | −0.319 | 0.152 | 0.149 | 0.462 |
Metabolic substrates | ||||||
Glucose | −0.241 | 0.060 | 0.409 | 0.051 | −0.168 | 0.377 |
Glycerol | 0.299 | 0.030 | 0.083 | 0.712 | −0.382 | 0.061 |
ǂ Acetoacetate | 0.443 | 0.001 * | −0.175 | 0.437 | −0.268 | 0.192 |
ǂ 3-hydroxybuturate | 0.319 | 0.002 * | −0.029 | 0.863 | −0.290 | 0.055 |
Acetate | −0.048 | 0.737 | 0.043 | 0.854 | 0.005 | 0.982 |
Citrate | 0.047 | 0.748 | −0.101 | 0.672 | 0.054 | 0.802 |
Lactate | 0.208 | 0.109 | −0.457 | 0.032 | 0.248 | 0.200 |
Pyruvate | −0.080 | 0.536 | 0.264 | 0.212 | −0.184 | 0.338 |
Amino acids | ||||||
Isoleucine (BCAA) | 0.262 | 0.073 | −0.274 | 0.252 | 0.011 | 0.959 |
Leucine (BCAA) | 0.339 | 0.019 | −0.354 | 0.135 | 0.015 | 0.946 |
Valine | 0.396 | 0.005 | −0.361 | 0.117 | −0.035 | 0.867 |
Alanine | 0.061 | 0.669 | −0.227 | 0.334 | 0.166 | 0.437 |
Glutamine | −0.059 | 0.649 | 0.149 | 0.485 | −0.090 | 0.644 |
Glycine | −0.159 | 0.253 | 0.250 | 0.271 | −0.091 | 0.659 |
Histidine | 0.101 | 0.483 | −0.412 | 0.082 | 0.310 | 0.148 |
Phenylalanine | 0.109 | 0.447 | −0.126 | 0.592 | 0.017 | 0.938 |
Tyrosine | −0.134 | 0.359 | 0.121 | 0.614 | 0.013 | 0.951 |
Miscellaneous | ||||||
Glycoproteins | 0.167 | 0.222 | −0.06 | 0.942 | −0.151 | 0.460 |
Creatinine | 0.201 | 0.159 | −0.352 | 0.132 | 0.151 | 0.476 |
Albumin | 0.071 | 0.572 | −0.400 | 0.052 | 0.329 | 0.079 |
High Sedentary Time and Low MVPA | Low Sedentary Time and High MVPA | ||||
---|---|---|---|---|---|
Metabolome Measure | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | p-Value |
Lipoprotein particle concentration | |||||
Extremely large VLDL | 1.0 × 10−10 (9.8 × 10−11) | 7.7 × 10−11 (8.6 × 10−11) | 8.6 × 10−11 (1.1 × 10−10) | 6.1 × 10−11 (1.1 × 10−10) | 0.097 1 |
Very large VLDL | 4.7 × 10−10 (5.8 × 10−10) | 2.7 × 10−10 (6.3 × 10−10) | 4.2 × 10−10 (6.1 × 10−10) | 2.1 × 10−10 (5.8 × 10−10) | 0.332 1 |
Large VLDL | 3.6 × 10−09 (3.3 × 10−09) | 2.4 × 10−09 (3.3 × 10−09) | 3.2 × 10−09 (3.5 × 10−09) | 2.3 × 10−09 (3.0 × 10−09) | 0.259 1 |
Medium VLDL | 1.5 × 10−08 (8.4 × 10−09) | 1.1 × 10−08 (9.0 × 10−09) | 1.3 × 10−08 (8.8 × 10−09) | 1.1 × 10−08 (7.8 × 10−09) | 0.251 1 |
Small VLDL | 2.6 × 10−08 (9.8 × 10−09) | 2.4 × 10−08 (1.3 × 10−08) | 2.4 × 10−08 (9.9 × 10−09) | 2.2 × 10−08 (5.4 × 10−08) | 0.174 1 |
Very small VLDL | 3.6 × 10−08 (8.5 × 10−09) | 3.5 × 10−08 (1.3 × 10−08) | 3.3 × 10−08 (7.7 × 10−09) | 3.3 × 10−08 (9.6 × 10−09) | 0.017 2 |
IDL | 9.9 × 10−08 (2.4 × 10−08) | 9.5 × 10−08 (3.7 × 10−08) | 8.9 × 10−08 (2.1 × 10−08) | 8.9 × 10−08 (2.6 × 10−08) | 0.009 2 |
Large LDL | 1.6 × 10−07 (4.3 × 10−08) | 1.6 × 10−07 (6.2 × 10−08) | 1.5 × 10−07 (3.7 × 10−08) | 1.4 × 10−07 (5.0 × 10−08) | 0.013 2 |
Medium LDL | 1.3 × 10−07 (3.7 × 10−08) | 1.3 × 10−07 (5.1 × 10−08) | 1.2 × 10−07 (3.2 × 10−08) | 1.2 × 10−07 (4.3 × 10−08) | 0.017 2 |
Small LDL | 1.5 × 10−07 (4.1 × 10−08) | 1.5 × 10−07 (5.6 × 10−08) | 1.4 × 10−07 (3.6 × 10−08) | 1.4 × 10−07 (4.7 × 10−08) | 0.023 2 |
Very large HDL | 3.7 × 10−07 (1.4 × 10−07) | 3.5 × 10−07 (2.0 × 10−07) | 3.9 × 10−07 (1.4 × 10−07) | 3.8 × 10−07 (2.1 × 10−07) | 0.331 2 |
Large HDL | 7.5 × 10−07 (3.4 × 10−07) | 7.5 × 10−07 (5.2 × 10−07) | 8.6 × 10−07 (3.6 × 10−07) | 8.3 × 10−07 (5.7 × 10−07) | 0.051 2 |
Medium HDL | 1.6 × 10−06 (2.4 × 10−07) | 1.5 × 10−06 (3.5 × 10−07) | 1.6 × 10−06 (2.4 × 10−07) | 1.6 × 10−06 (2.9 × 10−07) | 0.316 2 |
Small HDL | 4.6 × 10−06 (4.0 × 10−07) | 4.6 × 10−06 (6.3 × 10−07) | 4.5 × 10−06 (3.5 × 10−07) | 4.5 × 10−06 (4.4 × 10−07) | 0.348 2 |
Lipoprotein particle size | |||||
VLDL diameter | 36.4 (1.2) | 36.2 (1.4) | 36.3 (1.3) | 36.2 (1.7) | 0.639 2 |
LDL diameter | 23.6 (0.1) | 23.6 (0.1) | 23.6 (0.1) | 23.6 (0.1) | 0.912 2 |
HDL diameter | 9.8 (0.2) | 9.8 (0.4) | 9.8 (0.2) | 9.8 (0.3) | 0.121 2 |
Apolipoproteins | |||||
ApoA1 | 1.31 (0.12) | 1.27 (0.15) | 1.33 (0.13) | 1.34 (0.17) | 0.343 2 |
ApoB | 0.82 (0.19) | 0.80 (0.25) | 0.76 (0.17) | 0.75 (0.23) | 0.031 2 |
ApoB ApoA1 ratio | 0.63 (0.15) | 0.60 (0.19) | 0.57 (0.13) | 0.56 (0.16) | 0.015 2 |
Triglycerides | |||||
Total triglycerides | 1.07 (0.48) | 0.92 (0.53) | 0.99 (0.51) | 0.87 (0.44) | 0.158 1 |
VLDL TG | 0.73 (0.42) | 0.57 (0.45) | 0.67 (0.44) | 0.57 (0.38) | 0.232 1 |
IDL TG | 0.092 (0.022) | 0.090 (0.033) | 0.084 (0.023) | 0.080 (0.022) | 0.007 1 |
LDL TG | 0.14 (0.037) | 0.13 (0.053) | 0.12 (0.037) | 0.12 (0.040) | 0.010 1 |
HDL TG | 0.12 (0.029) | 0.11 (0.037) | 0.11 (0.031) | 0.10 (0.032) | 0.259 1 |
Cholesterol | |||||
Total cholesterol | 3.92 (0.79) | 3.85 (1.14) | 3.69 (0.73) | 3.65 (0.90) | 0.058 2 |
VLDL-C | 0.61 (0.23) | 0.58 (0.29) | 0.56 (0.23) | 0.52 (0.27) | 0.075 1 |
IDL-C | 0.64 (0.17) | 0.62 (0.24) | 0.58 (0.14) | 0.57 (0.18) | 0.012 2 |
LDL-C | 1.51 (0.45) | 1.46 (0.63) | 1.35 (0.39) | 1.34 (0.53) | 0.018 2 |
HDL-C | 1.16 (0.22) | 1.13 (0.27) | 1.21 (0.24) | 1.20 (0.35) | 0.154 2 |
HDL2-C | 0.67 (0.21) | 0.66 (0.26) | 0.72 (0.22) | 0.71 (0.32) | 0.117 2 |
HDL3-C | 0.49 (0.02) | 0.49 (0.03) | 0.49 (0.02) | 0.49 (0.03) | 0.543 2 |
Esterified cholesterol | 2.80 (0.57) | 2.76 (0.81) | 2.64 (0.52) | 2.60 (0.63) | 0.060 2 |
Free cholesterol | 1.12 (0.22) | 1.11 (0.33) | 1.06 (0.21) | 1.05 (0.25) | 0.057 2 |
Fatty acids | |||||
Total fatty acids | 9.41 (1.93) | 9.26 (2.62) | 8.95 (1.95) | 8.75 (2.40) | 0.137 2 |
Unsaturation degree | 1.22 (0.05) | 1.23 (0.06) | 1.24 (0.05) | 1.23 (0.05) | 0.060 2 |
Omega-3 FA | 0.36 (0.10) | 0.34 (0.13) | 0.34 (0.10) | 0.33 (0.12) | 0.442 2 |
Omega-3 FA ratio | 3.76 (0.57) | 3.65 (0.76) | 3.81 (0.59) | 3.73 (0.80) | 0.534 2 |
Docosahexaenoic acid | 0.096 (0.033) | 0.091 (0.043) | 0.090 (0.033) | 0.085 (0.038) | 0.277 2 |
Polyunsaturated FA | 3.72 (0.64) | 3.71 (0.84) | 3.59 (0.61) | 3.53 (0.74) | 0.199 2 |
Omega-6 FA | 3.36 (0.55) | 3.34 (0.74) | 3.25 (0.52) | 3.18 (0.69) | 0.176 2 |
Omega-6 FA ratio | 36.1 (2.6) | 36.5 (3.4) | 36.7 (2.7) | 37.3 (3.2) | 0.138 2 |
Linoleic acid | 2.89 (0.47) | 2.89 (0.7) | 2.81 (0.44) | 2.76 (0.59) | 0.266 2 |
Saturated FA | 3.23 (0.68) | 3.16 (0.95) | 3.02 (0.69) | 2.96 (0.85) | 0.064 2 |
Saturated FA ratio | 34.27 (1.00) | 34.39 (1.24) | 33.74 (1.06) | 33.85 (1.30) | 0.001 2,* |
Monounsaturated FA | 2.47 (0.70) | 2.34 (0.90) | 2.34 (0.73) | 2.25 (0.86) | 0.132 1 |
Metabolic substrates | |||||
Glucose | 4.00 (0.38) | 3.96 (0.49) | 4.04 (0.36) | 4.04 (0.42) | 0.356 1 |
Glycerol | 0.072 (0.023) | 0.066 (0.027) | 0.063 (0.019) | 0.061 (0.022) | 0.008 1 |
Acetoacetate | 0.119 (0.080) | 0.095 (0.100) | 0.081 (0.053) | 0.059 (0.048) | <0.001 1,* |
3-hydroxybuturate | 0.21 (0.13) | 0.17 (0.15) | 0.16 (0.10) | 0.13 (0.07) | <0.001 1,* |
Acetate | 0.044 (0.009) | 0.043 (0.014) | 0.043 (0.010) | 0.042 (0.013) | 0.532 2 |
Citrate | 0.107 (0.011) | 0.107 (0.016) | 0.107 (0.012) | 0.105 (0.017) | 0.749 2 |
Lactate | 0.92 (0.24) | 0.89 (0.31) | 0.89 (0.23) | 0.81 (0.32) | 0.263 1 |
Pyruvate | 0.079 (0.017) | 0.077 (0.018) | 0.075 (0.013) | 0.075 (0.018) | 0.150 2 |
Amino acids | |||||
Isoleucine (BCAA) | 0.058 (0.012) | 0.057 (0.015) | 0.056 (0.015) | 0.054 (0.017) | 0.096 1 |
Leucine (BCAA) | 0.085 (0.013) | 0.084 (0.017) | 0.081 (0.015) | 0.079 (0.019) | 0.139 2 |
Valine | 0.184 (0.023) | 0.184 (0.039) | 0.178 (0.027) | 0.181 (0.034) | 0.132 2 |
Alanine | 0.365 (0.052) | 0.361 (0.070) | 0.359 (0.042) | 0.347 (0.058) | 0.445 2 |
Glutamine | 0.502 (0.059) | 0.498 (0.078) | 0.537 (0.085) | 0.529 (0.103) | 0.005 1 |
Glycine | 0.229 (0.027) | 0.224 (0.032) | 0.233 (0.027) | 0.232 (0.034) | 0.282 1 |
Histidine | 0.069 (0.006) | 0.069 (0.009) | 0.069 (0.007) | 0.069 (0.009) | 0.737 1 |
Phenylalanine | 0.068 (0.009) | 0.066 (0.010) | 0.068 (0.007) | 0.067 (0.007) | 0.741 2 |
Tyrosine | 0.051 (0.009) | 0.05 (0.013) | 0.052 (0.009) | 0.053 (0.011) | 0.496 2 |
Miscellaneous | |||||
Glycoproteins | 1.25 (0.18) | 1.21 (0.23) | 1.23 (0.17) | 1.20 (0.17) | 0.566 1 |
Creatinine | 0.071 (0.009) | 0.070 (0.012) | 0.069 (0.008) | 0.069 (0.011) | 0.159 2 |
Albumin | 0.089 (0.005) | 0.089 (0.007) | 0.089 (0.005) | 0.089 (0.007) | 0.572 2 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vaara, J.P.; Kyröläinen, H.; Vasankari, T.; Kainulainen, H.; Raitanen, J.; Kujala, U.M. Accelerometer-Based Sedentary Time, Physical Activity, and Serum Metabolome in Young Men. Metabolites 2022, 12, 700. https://doi.org/10.3390/metabo12080700
Vaara JP, Kyröläinen H, Vasankari T, Kainulainen H, Raitanen J, Kujala UM. Accelerometer-Based Sedentary Time, Physical Activity, and Serum Metabolome in Young Men. Metabolites. 2022; 12(8):700. https://doi.org/10.3390/metabo12080700
Chicago/Turabian StyleVaara, Jani P., Heikki Kyröläinen, Tommi Vasankari, Heikki Kainulainen, Jani Raitanen, and Urho M Kujala. 2022. "Accelerometer-Based Sedentary Time, Physical Activity, and Serum Metabolome in Young Men" Metabolites 12, no. 8: 700. https://doi.org/10.3390/metabo12080700
APA StyleVaara, J. P., Kyröläinen, H., Vasankari, T., Kainulainen, H., Raitanen, J., & Kujala, U. M. (2022). Accelerometer-Based Sedentary Time, Physical Activity, and Serum Metabolome in Young Men. Metabolites, 12(8), 700. https://doi.org/10.3390/metabo12080700